- Summits
- Sponsorship
- Media Opportunities
- News
- About
Corporate venture capital significantly alters the investment environment for Medtech. However, raising this capital requires more than a good valuation pitch. In the panel session entitled “Strategic Money, Strategic Risk: What Do Corporate Ventures Really Want From MedTech,” held at the MedTech World North America Summit 2026, leaders from various companies provided insight into how corporate investors evaluate their expected financial return from Medtech companies and the strategic value of investing in Medtech over time.
Held on 13 May in the Oceana Ballroom at the Hilton West Palm Beach, the session brought together voices from investment analysis, healthcare technology, and innovation strategy. The discussion featured Matt Henriksson, Komeil Nasrollahi, Dr Steven Mickelsen, and Mayank Vijayvergia.
The strongest theme of this panel was the difference between conventional venture capital and corporate venture investments. Although the financial picture remains very important, the corporate investor also considers strategic fit key.
The panel noted that many MedTech startups misinterpret corporate investors’ expectations and focus primarily on product innovation or near-term commercial opportunities. Corporate venture groups assess how a particular technology fits into the broader ecosystem, aligns with the current product portfolio, and will help position the company in the market over the long term.
Representatives from GE Healthcare and Siemens Healthineers stated that strategic investors will look not only for passive financial returns but also for partnerships with organizations capable of delivering operational synergies, accelerating innovation, and meeting the changing demands of healthcare.
There was also some discussion about how startups should begin approaching these kinds of relationships with an understanding of the corporate investor’s business model, timelines and priorities. Corporate investors often have a longer-term focus than independent venture capital firms and therefore make decisions based on their business integration opportunities and sector-specific growth strategies.
Another topic of interest during the session was risk assessment. The main point made by presenters was that corporate venture capital investors view risk from different perspectives, not simply via the financial; they also consider whether a product is adequately positioned from the regulatory perspective, if it can be scaled up effectively, if there are established reimbursement pathways, if there is clinical validation, and if the product can be integrated effectively into the current health system.
The founder’s perspective was articulated by Dr. Steven Mickelsen, who discussed the hurdles that start-ups encounter when seeking to develop partnerships with large healthcare corporations and stressed the importance of operational maturity and transparency for large corporations when determining whether to partner with a start-up. For a corporation to enter into a partnership, it must have confidence in both the product and the company’s leadership team, and their long-term strategy must align with the corporation’s vision for developing a long-term partnership.
The panel also discussed how investors are placing increased pressure on healthcare technology companies to provide measurable, quantifiable patient outcomes that demonstrate they are creating efficiencies, decreasing costs, or enhancing clinical performance in real-world healthcare environments.
A soft yet consistent message in this conversation was that successful corporate venture relationships hinge on collaboration, not transactional investment alone. The panellists identified the best partnerships as those where startups and their corporate investors work in concert to create solutions to industry-wide challenges.
The panel encouraged entrepreneurs creating startups to view corporations as more than just a source of funding; they offered insight into the broader value that corporate partnerships can provide. Panelists identified numerous resources available through corporate partners, such as access to distribution networks, regulatory expertise, manufacturing infrastructure, and established relationships with healthcare providers. Each of these resources can help accelerate the commercial growth of new ventures.
The panellists urged entrepreneurs considering a corporate partnership to fully understand the strategic implications of entering into one. Miscommunication, misaligned expectations, or differing goals between the startup and corporate partners can create more barriers to innovation than they do new opportunities.
The panel reflected broader shifts taking place across the healthcare investment sector. As economic conditions remain uncertain and innovation cycles continue to accelerate, corporate venture capital is becoming increasingly influential in shaping the future of MedTech.
Panellists agreed that investors are placing greater emphasis on technologies capable of delivering practical, scalable healthcare solutions that fit within larger strategic healthcare ecosystems. Companies that can demonstrate both clinical value and alignment with long-term industry priorities are likely to remain attractive targets for corporate investment.
The session offered attendees a clearer picture of how healthcare corporations are approaching innovation partnerships in 2026, while also providing founders with valuable insights on positioning themselves for long-term strategic growth.
To learn more about the MedTech World North America Summit, check out the full agenda.
